Laquinimod-d5
Based on 1 Customer Validation
Laquinimod-d5 (ABR-215062-d5) is deuterium labeled Laquinimod. Laquinimod (ABR-215062), an orally available carboxamide derivative, is a potent immunomodulator that prevents neurodegeneration and inflammation in the central nervous system. Laquinimod reduces astrocytic NF-κB activation to protect from Cuprizone-induced demyelination. Laquinimod has the potential for relapsing-remitting (RR) and chronic progressive (CP) forms of multiple sclerosis (MS; RRMS or CPMS) as well as neurodegenerative diseases research.
For research use only. We do not sell to patients.
- Purity : 98.25%
- CAS No.: 1214267-09-0
- Formula: C19H12D5ClN2O3
- Molecular Weight:361.83
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
Application
1. This compound can be used as a tracer
2. This compound can be used as an internal standard for quantitative analysis by NMR, GC-MS, or LC-MS.
Chemical Information
-
CAS No. 1214267-09-0
-
Unlabeled CAS 248281-84-7
-
Appearance Solid
-
Molecular Weight 361.83
-
Formula C19H12D5ClN2O3
-
Color White to light yellow
-
SMILES
[2H]C1=C([2H])C([2H])=C(N(C(C2=C(O)C3=C(N(C)C2=O)C=CC=C3Cl)=O)CC)C([2H])=C1[2H]
-
Synonyms
ABR-215062-d5
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvent & Solubility
In Vitro:
DMSO : 100 mg/mL (276.37 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Protocols
-
Neurotoxicity Study
This protocol assesses in vitro neurotoxicity by combining neuronal viability, mitochondrial/metabolic activity, neurite outgrowth, and optional neuronal network function readouts. Calcein-AM or resazurin/PrestoBlue readouts estimate viable or metabolically active cells; βIII-tubulin immunofluorescence detects neuronal morphology and neurite networks; TMRE detects mitochondrial membrane potential; and MEA recordings detect functional changes in neuronal network activity.
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
Purity & Documentation
-
Data Sheet (274 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.7637 mL | 13.8186 mL | 27.6373 mL | 69.0932 mL |
| 5 mM | 0.5527 mL | 2.7637 mL | 5.5275 mL | 13.8186 mL | |
| 10 mM | 0.2764 mL | 1.3819 mL | 2.7637 mL | 6.9093 mL | |
| 15 mM | 0.1842 mL | 0.9212 mL | 1.8425 mL | 4.6062 mL | |
| 20 mM | 0.1382 mL | 0.6909 mL | 1.3819 mL | 3.4547 mL | |
| 25 mM | 0.1105 mL | 0.5527 mL | 1.1055 mL | 2.7637 mL | |
| 30 mM | 0.0921 mL | 0.4606 mL | 0.9212 mL | 2.3031 mL | |
| 40 mM | 0.0691 mL | 0.3455 mL | 0.6909 mL | 1.7273 mL | |
| 50 mM | 0.0553 mL | 0.2764 mL | 0.5527 mL | 1.3819 mL | |
| 60 mM | 0.0461 mL | 0.2303 mL | 0.4606 mL | 1.1516 mL | |
| 80 mM | 0.0345 mL | 0.1727 mL | 0.3455 mL | 0.8637 mL | |
| 100 mM | 0.0276 mL | 0.1382 mL | 0.2764 mL | 0.6909 mL |
Laquinimod-d5 Related Classifications
HY-13010S Related Classifications
Powered by Bioz